期刊文献+

胃腺癌中survivin和EGFR的作用及其相互关系 被引量:2

Role of the survivin and EGFR in gastric cancer and their correlation
下载PDF
导出
摘要 目的探讨survivin及表皮生长因子受体EGFR在胃癌中的表达作用及二者的相关性。方法应用免疫组织化学的方法检测60例胃腺癌中survivin及EGFR的表达,采用MTT法观察EGFR抑制剂AG1478对胃癌细胞生长的影响,FCM法检测细胞凋亡,蛋白质印迹分析方法检测survivin的表达变化。结果 EGFR和survivin在胃癌组织中的表达显著高于在正常胃组织中的表达(P<0.05),并且EGFR与survivin的表达具有相关性(r=0.587,P<0.005);EGFR抑制剂AG1478能够抑制胃癌细胞SGC7901的增殖,并能够诱导凋亡,并下调survivin的表达。结论 survivin和EGFR在胃癌中的表达具有相关性,并且survivin可能在EGFR引起的肿瘤细胞增殖中发挥着重要作用。survivin和EGFR有望成为胃癌治疗的联合靶点。 Objective To explore the role of EGFR and survivin in the gastric cancer and their correlation.Methods The expression of EGFR and survivin was measured in gastric adenocarcinoma by immnohistochemistry.Human gastric cancer cell line SGC-7901 was cultured and treated with different concentrations of AG1478,then the proliferation of SGC-7901 cells was determined by MTT,the apoptosis was detected by FCM,and the survivin expression was determined by Western blot.Results The expression of EGFR and survivin protein was significantly higher in gastric adenocarcinoma tissues than those in normal gastric epithelium.And there was positive correlation between EGFR and survivin expression in gastric adenocarcinoma.The AG1478 inhibited the cell proliferation,increased the apoptosis of SGC7901,and downregulated the expression of survivin.Conclusion The results suggest that survivin may play an important role in tumor cell proliferation induced by EGFR.Survivin and EGFR are promising to be a combined therapeutic strategy in gastric cancer.
出处 《山西医科大学学报》 CAS 2014年第9期839-842,903,904,共6页 Journal of Shanxi Medical University
基金 陕西省教育厅科研计划基金资助项目(12JK0765) 西安医学院科研基金资助项目(11FZ07) 西安医学院第一附属医院科研基金资助项目(XYFY10-04)
关键词 SURVIVIN 表皮生长因子受体 胃腺癌 增殖 survivin EGFR gastric adenocarcinoma cell proliferation
  • 相关文献

参考文献11

  • 1Kajiwara Y,Yamasaki F,Hama S,et al.Expression of survivin in astrocytic tumors:correlation with malignant grade and prognosis[J].Cancer,2003,97:1077-1083.
  • 2Kennedy SM,O' Driscoll L,Purcell R,et al.Prognostic importance of survivin in breast cancer[J].Br J Cancer,2003,88:1077-1083.
  • 3Altieri DC.Validating survivin as a cancer therapeutic target[J].Nat Rev Cancer,2003,3:46-54.
  • 4Abd El-Rehim DM,Pinder SE,Paish CE,et al.Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma[J].Br J Cancer,2004,91:1532-1542.
  • 5Berger LA,Riesenberg H,Bokemeyer C,et al.CNS metastases in non-small cell lung cancer:current role of EGFR-TKI therapy and future perspectives[J].Lung Cancer,2013,80 (3):242-248.
  • 6Danielsen AJ,Maihle NJ.The EGF/ErbB receptor family and apoptosis[J].Growth Factors,2002,20:1-15.
  • 7Normanno N,De Luca A,Maiello MR,et al.Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer:current status and future development[J].Front Biosci,2005,10:2611-2617.
  • 8Asahina H,Yamazaki K,Kinoshita I,et al.A phase Ⅱ trial of gefitinib as frist-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations[J].Br J Cancer,2006,95(8):998-1004.
  • 9Reis-Filho JS,Milanezi F,Carvalho S,et al.Metaplastic breast carcinomas exhibit EGFR,but not HER2,gene amplification and overexpression:immunohistochemical and chromogenic in situ hybridization analysis[J].Breast Cancer Res,2005,7:1028-1035.
  • 10曹卫国,马韬,李建芳,黎皓,纪玉宝,陈雪华,刘炳亚,金冶宁.吉非替尼对胃癌细胞株放射增敏的作用[J].癌症,2007,26(12):1330-1335. 被引量:14

二级参考文献11

  • 1王明国,王中和,胡海生.表皮生长因子受体抗体对人舌鳞癌细胞增殖和放射敏感性的影响[J].中华放射肿瘤学杂志,2004,13(4):334-334. 被引量:7
  • 2Macdonald J S, Smalley S R, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J]. N Engl J Med, 2001,345(10):725-730.
  • 3刘桂芬.半数效量[M]//蒋知俭.医学统计学.北京:人民卫生出版社,1997:136-153.
  • 4Herbst R S, Langer C J. Epidermal growth factor receptors as atarget for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers [J]. Semin Oncol, 2002,29(Suppl 4) : 27-36.
  • 5Akimoto T, Hunter N R, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radio curability of murine carcinomas [J]. Clin Cancer Res, 1999,5(10) :2884-2890.
  • 6Nicholson R I, Gee J M, Harper M E. EGFR and cancer prognosis [J]. Eur J Cancer, 2001,37(Suppl 4):S9-15.
  • 7Slichenmyer W J, Fry D W. Anticancer therapy targeting in erbB family of receptor tyrosine kinase [J]. Semin Oncol, 2001,28(suppl 16): 67-79.
  • 8Williams K J, Teller B A, Stratford I J, et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptortyrosine kinase inhibitor, potentiates radiotherapy in a human eoloreetal cancer xenograft model [J]. Br J Cancer, 2002,86 (7) : 1157-1161.
  • 9Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) [J]. Olin Cancer Res, 2002,8(10): 3250-3258.
  • 10Miller V A, Johnson D H, Heclan R T, et al. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer [J]. Proc Am Soc Clin Oncol, 2001,20: (abstr)1301.

共引文献13

同被引文献29

  • 1Salazar N,Munoz D,Singh RK,et al. The heterotypic interac-tion between CXCR7 and EGFR is an alternative proliferationmechanism in breast cancer[J]. Cancer Res,2014,74(19 Sup-plement) :3336-3336.
  • 2Gaule PB,Crown J,QDonovan N,et al. cMET in triple-nega-tive breast cancer: is it a therapeutic target for this subset ofbreast cancer patients. [J]. Expert Opin Ther Tar,2014,18(9): 999-1009.
  • 3Volinia S,Nuovo G,Drusco A, et al. Pluripotent stem cellmiRNAs and metastasis in invasive breast cancer [J]. J NatCancer Ins, 2014,106(12): 324-331.
  • 4Lange JM, Takashima JR, Peterson SM,et al. Breast cancer in femalesurvivors of Wilms tumor: A report from the National Wilms Tlimorlate effects study[J]. Cancer, 2014, 120(23) : 3722-3730.
  • 5Giles KM, Brown RAM, Epis MR, et al. miRNA-7-5p inhibitsmelanoma cell migration and invasion [J]. Biochem Bioph ResComm, 2013,430(2): 706-710.
  • 6Liu Z, Liu Y,Li L,et al. MiR-7-5p is frequently downregulatedin glioblastoma microvasculature and inhibits vascular endothelialcell proliferation by targeting RAF1[J]. Tumor Biology, 2014,35(10):10177-10184.
  • 7Mader CC, Oser M,Magalhaes MAO, et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of inv-adopodia and breast cancer cell invasion[J]. Cancer Res, 2011,71(5): 1730-1741.
  • 8袁光波,郭建新,陈蜜,徐正阳,娄鹏荣,陶庆松.慢病毒介导的miRNA逆转胃癌细胞耐药性研究[J].中华肿瘤防治杂志,2013,20(4):254-257. 被引量:2
  • 9邢春瑶,冷维春,周家文.Bcl-2和Survivin在宫颈癌中的研究进展[J].中国实验诊断学,2014,18(1):167-169. 被引量:14
  • 10胡金甫,汪辉,李科珍.Survivin、Bcl-2、HPV16/18在宫颈癌中的表达及相关性研究[J].中国妇幼保健,2014,29(5):781-784. 被引量:8

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部